Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
about
Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysisThe Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in MiceEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 TrialIpragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusEfficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsA randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with typeEffects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus.Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
P2860
Q28072765-F0B98405-E42E-479A-8E9C-64E480D5186CQ28076978-8C2AF5C0-FD85-49DC-926B-24585B04E7C5Q28552063-59441484-C6D8-4262-8C82-E68C453432AFQ30248634-FFB5BCDA-0862-4425-BD92-62BFEA130F6AQ31117903-CD3B93DE-9B26-4779-A2D1-A3FEB4E6E98EQ33614337-2A8CC6A5-97EA-4446-8BC8-4525A71A4556Q33763305-8EB58EF0-C363-4368-B02D-C22CF77CDF2AQ33871321-2F75924B-BD17-4DFA-94C7-96E32D3BD25BQ36429733-4ACEF9FF-28BC-4D00-9DDE-EC5A5F44BE96Q36843902-E4EA4A49-9809-47FD-85FB-63E73FF6935AQ37060855-71FF0FE8-15A9-4B5F-82F7-DADE5D5BCA99Q37114983-0C018B12-F32E-45D9-8CBF-31EB54A069CDQ37257445-FF8CC9D9-20A9-4CE5-96BB-34A2DE86B583Q37559899-4B4CF4B4-D000-4283-81F5-BB08BC4975E1Q38260349-524B558E-BFEE-4305-9BCE-46BA1034D5CAQ38340949-A1C3BF0A-8B6A-4ACB-81C7-843211E280C0Q38396879-E07EFCDE-2C63-4E2F-B844-A64869E51A11Q38614488-2D6ADC5E-C725-4177-9B86-230B2DA5E130Q39393777-9479611C-969F-4BE3-9475-6AFC4B111AC8Q39401928-73ED33B0-3A1C-4922-BCF3-9C8997FBE205Q39540260-FE4426A9-B60E-44F0-9497-462C4845BF1FQ39879822-3B05FAE4-CC43-49EE-B40B-C981FA84B108Q40106543-6ADA9319-6090-46A1-AA78-1703F79D00EDQ40606871-EA19DD96-3728-43F3-859A-947E0D914B2FQ42688847-DA295559-2B3C-44B1-B177-E1C04E1180CBQ47398293-6E78A2D1-FF5B-4137-BBF5-A42AC4554B06Q47995019-273B4413-0ADD-45DF-BFFD-DD226040188CQ48189020-5C6CE3CE-E7D8-4821-B830-E3548224E28FQ51034590-DA6A009A-639E-4D22-A2A3-D545EBA77D6D
P2860
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Ipragliflozin in combination w ...... ind, placebo-controlled study.
@en
Ipragliflozin in combination w ...... ind, placebo-controlled study.
@nl
type
label
Ipragliflozin in combination w ...... ind, placebo-controlled study.
@en
Ipragliflozin in combination w ...... ind, placebo-controlled study.
@nl
prefLabel
Ipragliflozin in combination w ...... ind, placebo-controlled study.
@en
Ipragliflozin in combination w ...... ind, placebo-controlled study.
@nl
P2093
P2860
P921
P356
P1476
Ipragliflozin in combination w ...... ind, placebo-controlled study.
@en
P2093
P2860
P304
P356
10.1111/DOM.12331
P577
2014-07-31T00:00:00Z